Six-month low-dose valganciclovir prophylaxis in cytomegalovirus D+/R- kidney transplant patients receiving thymoglobulin induction (Q44838872)

6 December 2017

Six-month low-dose valganciclovir prophylaxis in cytomegalovirus D+/R- kidney transplant patients receiving thymoglobulin induction (English)

1 reference

6 December 2017

0 references

1 reference

F L Luan

1

1 reference

PubMed ID

23267799

6 December 2017

language of work or name

English

0 references

publication date

10 September 2012

1 reference

Transplantation Proceedings

6 December 2017

1 reference

6 December 2017

45

1 reference

6 December 2017

1

1 reference

6 December 2017

175-177

1 reference

A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients

6 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.04.036

Cytomegalovirus disease in high-risk transplant recipients despite ganciclovir or valganciclovir prophylaxis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.04.036

Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.04.036

Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.04.036

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.04.036

Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.04.036

Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.04.036

IMPACT trial results should not change current standard of care of 100 days for cytomegalovirus prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.04.036

The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.04.036

Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.04.036

Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.04.036

Effectiveness of valganciclovir 900 mg versus 450 mg for cytomegalovirus prophylaxis in transplantation: direct and indirect treatment comparison meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.04.036

Immunosuppression: evolution in practice and trends, 1994-2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.04.036

Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.04.036

Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.04.036

Hospitalizations for cytomegalovirus disease after renal transplantation in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.04.036

Persistent cytomegalovirus infection in kidney allografts is associated with inferior graft function and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.04.036

Impact of cytomegalovirus disease in D+/R- kidney transplant patients receiving 6 months low-dose valganciclovir prophylaxis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2012.04.036

10.1016/J.TRANSPROCEED.2012.04.036

7 January 2021

Identifiers

DOI

1 reference

6 December 2017

1 reference

PubMed ID

23267799